Atlas Trials

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients

Clinical trial NCT01222052 · UNKNOWN

Trial details

NCT number
NCT01222052
Sponsor
Martin-Luther-Universität Halle-Wittenberg
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2002-01-01
Primary completion
2009-02-01
Enrollment
4150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.